Home The Word Brain	My Amedeo FAQ Privacy About
	As of October 2023, Amedeo had 12,263 active subscribers

Peptic Ulcer

Free Subscription Articles published in Aliment Pharmacol Ther Retrieve available abstracts of 68 articles: HTML format

Single Articles

August 2023
1. GONG EJ, Jung HK, Lee B, Hong J, et al
   Proton pump inhibitor use and the risk of metachronous gastric cancer after H. pylori eradication in patients who underwent endoscopic resection for gastric neoplasms: A population-based cohort study.
   Aliment Pharmacol Ther. 2023 Aug 17. doi: 10.1111/apt.17676.
   PubMed     Abstract available
   
   
   July 2023
2. WAUTERS L, Harris PR, Walker MM, Serrano CA, et al
   Letter: childhood recurrent abdominal pain is associated with increased duodenal eosinophilia independent of Helicobacter pylori infection.
   Aliment Pharmacol Ther. 2023;58:134-136.
   PubMed    
   
   
   May 2023
3. PIOVANI D, Tsantes AG, Schunemann HJ, Bonovas S, et al
   Letter: Potassium-competitive acid blockers may increase the risk of gastric cancer after Helicobacter pylori eradication-a retrospective multicentre-cohort analysis. Authors' reply.
   Aliment Pharmacol Ther. 2023;57:1199-1200.
   PubMed    
   
   
   
4. KOUNTOURAS J, Papaefthymiou A, Polyzos SA, Kazakos E, et al
   Letter: higher severe outcomes among Helicobacter pylori-related lean patients with non-alcoholic fatty liver disease and metabolic comorbidities.
   Aliment Pharmacol Ther. 2023;57:1186-1187.
   PubMed    
   
   
   
5. ARAI J, Hayakawa Y, Niikura R, Ihara S, et al
   Letter: Potassium-competitive acid blockers may increase the risk of gastric cancer after Helicobacter pylori eradication a retrospective multicentre-cohort analysis.
   Aliment Pharmacol Ther. 2023;57:1196-1198.
   PubMed    
   
   
   April 2023
6. HOWDEN CW, Shah S, Pendse SN, Offman E, et al
   Physiologically based pharmacokinetic modelling to predict intragastric rifabutin concentrations in the treatment of Helicobacter pylori infection.
   Aliment Pharmacol Ther. 2023 Apr 20. doi: 10.1111/apt.17526.
   PubMed     Abstract available
   
   
   
7. SCARPIGNATO C, Howden CW, Leifke E, Mulford DJ, et al
   A translational pharmacokinetic/pharmacodynamic approach supports optimal vonoprazan dosing for erosive oesophagitis and Helicobacter pylori infection.
   Aliment Pharmacol Ther. 2023 Apr 17. doi: 10.1111/apt.17510.
   PubMed     Abstract available
   
   
   March 2023
8. TAILLIEU E, De Witte C, De Schepper H, Van Moerkercke W, et al
   Clinical significance and impact of gastric non-Helicobacter pylori Helicobacter species in gastric disease.
   Aliment Pharmacol Ther. 2023 Mar 28. doi: 10.1111/apt.17488.
   PubMed     Abstract available
   
   
   January 2023
9. POMENTI S, Katzka DA
   Editorial: P-CABs for treatment of reflux oesophagitis-is this the future?
   Aliment Pharmacol Ther. 2023;57:146-147.
   PubMed    
   
   
   December 2022
10. PIOVANI D, Tsantes AG, Schunemann HJ, Bonovas S, et al
    Meta-analysis: Use of proton pump inhibitors and risk of gastric cancer in patients requiring gastric acid suppression.
    Aliment Pharmacol Ther. 2022 Dec 31. doi: 10.1111/apt.17360.
    PubMed     Abstract available
    
    
    
11. HUI S, Lim A, Koh E, Abasszade J, et al
    Prevalence and prognostic significance of vitamin C deficiency in patients with acute upper gastrointestinal bleeding: a prospective cohort study.
    Aliment Pharmacol Ther. 2022 Dec 13. doi: 10.1111/apt.17359.
    PubMed     Abstract available
    
    
    October 2022
12. CHO YK, Kim JH, Kim HS, Kim TO, et al
    Randomised clinical trial: comparison of tegoprazan and lansoprazole as maintenance therapy for healed mild erosive oesophagitis.
    Aliment Pharmacol Ther. 2022 Oct 31. doi: 10.1111/apt.17255.
    PubMed     Abstract available
    
    
    
13. YADLAPATI R, Gawron AJ, Gyawali CP, Chen J, et al
    Clinical role of ambulatory reflux monitoring in PPI non-responders: recommendation statements.
    Aliment Pharmacol Ther. 2022;56:1274-1283.
    PubMed     Abstract available
    
    
    September 2022
14. ANG D, Koo SH
    Editorial: slow progress to optimising H. pylori eradication treatment with antisecretory drugs-authors' reply.
    Aliment Pharmacol Ther. 2022;56:1076-1077.
    PubMed    
    
    
    
15. GISBERT JP, Hunt RH
    Editorial: slow progress to optimising H. pylori eradication treatment with antisecretory drugs.
    Aliment Pharmacol Ther. 2022;56:1074-1075.
    PubMed    
    
    
    August 2022
16. RAYMENANTS K, Tack J
    Editorial: refractory reflux sensitivity-A place for baclofen? Authors' reply.
    Aliment Pharmacol Ther. 2022;56:725-726.
    PubMed    
    
    
    
17. KATZ PO
    Editorial: refractory reflux sensitivity - a place for baclofen?
    Aliment Pharmacol Ther. 2022;56:723-724.
    PubMed    
    
    
    
18. ANG D
    Letter: a promising Helicobacter pylori regimen-vonoprazan-based therapy. Author's reply.
    Aliment Pharmacol Ther. 2022;56:754-755.
    PubMed    
    
    
    
19. HU Y, Lu NH
    Letter: a promising Helicobacter pylori regimen - vonoprazan-based therapy.
    Aliment Pharmacol Ther. 2022;56:752-753.
    PubMed    
    
    
    July 2022
20. YEOMANS ND
    Editorial: risk of gastric and duodenal ulcers among new users of low-dose aspirin.
    Aliment Pharmacol Ther. 2022;56:334-335.
    PubMed    
    
    
    
21. RADADIYA D, Devani K, Rockey DC
    Editorial: the impact of red blood cell transfusion on inpatient mortality in upper gastrointestinal bleeding-authors' reply.
    Aliment Pharmacol Ther. 2022;56:338-339.
    PubMed    
    
    
    
22. ORPEN-PALMER J, Stanley AJ
    Editorial: the impact of red blood cell transfusion on inpatient mortality in upper gastrointestinal bleeding.
    Aliment Pharmacol Ther. 2022;56:336-337.
    PubMed    
    
    
    June 2022
23. ANG D, Koo SH, Chan YH, Tan TY, et al
    Clinical trial: seven-day vonoprazan- versus 14-day proton pump inhibitor-based triple therapy for first-line Helicobacter pylori eradication.
    Aliment Pharmacol Ther. 2022 Jun 3. doi: 10.1111/apt.17070.
    PubMed     Abstract available
    
    
    
24. PAUWELS A, Raymenants K, Geeraerts A, Boecxstaens V, et al
    Clinical trial: a controlled trial of baclofen add-on therapy in PPI-refractory gastro-oesophageal reflux symptoms.
    Aliment Pharmacol Ther. 2022 Jun 3. doi: 10.1111/apt.17068.
    PubMed     Abstract available
    
    
    
25. SONNENBERG A
    Letter: birth cohort pattern of Helicobacter pylori infection rates.
    Aliment Pharmacol Ther. 2022;55:1461.
    PubMed    
    
    
    
26. CHEN S, Liu D, Chen H, Liao A, et al
    The efficacy and safety of keverprazan, a novel potassium-competitive acid blocker, in treating erosive oesophagitis: a phase III, randomised, double-blind multicentre study.
    Aliment Pharmacol Ther. 2022;55:1524-1533.
    PubMed     Abstract available
    
    
    May 2022
27. NGUYEN TNM, Sha S, Chen LJ, Holleczek B, et al
    Strongly increased risk of gastric and duodenal ulcers among new users of low-dose aspirin: Results from two large cohorts with new-user design.
    Aliment Pharmacol Ther. 2022 May 27. doi: 10.1111/apt.17050.
    PubMed     Abstract available
    
    
    February 2022
28. JIANG F, Guo CG, Leung WK
    Letter: the hidden reasons of long-term risk of upper gastrointestinal bleeding after Helicobacter pylori eradication-authors' reply.
    Aliment Pharmacol Ther. 2022;55:374-375.
    PubMed    
    
    
    
29. YANG H, Hu B
    Letter: the hidden reasons of long-term risk of upper gastrointestinal bleeding after Helicobacter pylori eradication.
    Aliment Pharmacol Ther. 2022;55:372-373.
    PubMed    
    
    
    January 2022
30. ZHENG X, Li N, Zhao J
    Letter: proton pump inhibitors and risk of myocardial infarction.
    Aliment Pharmacol Ther. 2022;55:139-140.
    PubMed    
    
    
    
31. NOLDE M, Ahn N, Dreischulte T, Ruckert-Eheberg IM, et al
    Letter: proton pump inhibitors and risk of myocardial infarction-authors' reply.
    Aliment Pharmacol Ther. 2022;55:141-142.
    PubMed    
    
    
    
32. YANG JC, Kao JY
    Treatment considerations in Helicobacter pylori management.
    Aliment Pharmacol Ther. 2022;55 Suppl 1:S22-S28.
    PubMed    
    
    
    
33. DORE MP, Graham DY
    Modern approach to the diagnosis of Helicobacter pylori infection.
    Aliment Pharmacol Ther. 2022;55 Suppl 1:S14-S21.
    PubMed    
    
    
    
34. SONNENBERG A
    Epidemiology of Helicobacter pylori.
    Aliment Pharmacol Ther. 2022;55 Suppl 1:S1-S13.
    PubMed     Abstract available
    
    
    November 2021
35. SUGANO K, Howden CW
    Editorial: the never-ending story-Helicobacter pylori and peptic ulcer disease.
    Aliment Pharmacol Ther. 2021;54:1350-1351.
    PubMed    
    
    
    
36. JIANG F, Guo CG, Leung WK
    Editorial: the never-ending story-Helicobacter pylori and peptic ulcer disease. Authors' reply.
    Aliment Pharmacol Ther. 2021;54:1352-1353.
    PubMed    
    
    
    October 2021
37. SCHUITENMAKER JM, Oude Nijhuis RAB, Bredenoord AJ
    Letter: is wireless oesophageal pH monitoring the best technique to evaluate night-time reflux? Authors' reply.
    Aliment Pharmacol Ther. 2021;54:976.
    PubMed    
    
    
    
38. RIBOLSI M, Savarino E
    Letter: is wireless oesophageal pH monitoring the best technique to evaluate night-time reflux?
    Aliment Pharmacol Ther. 2021;54:974-975.
    PubMed    
    
    
    September 2021
39. JIANG F, Guo CG, Cheung KS, Leung WK, et al
    Long-term risk of upper gastrointestinal bleeding after Helicobacter pylori eradication: a population-based cohort study.
    Aliment Pharmacol Ther. 2021 Sep 16. doi: 10.1111/apt.16604.
    PubMed     Abstract available
    
    
    
40. NOLDE M, Ahn N, Dreischulte T, Ruckert-Eheberg IM, et al
    The long-term risk for myocardial infarction or stroke after proton pump inhibitor therapy (2008-2018).
    Aliment Pharmacol Ther. 2021 Sep 3. doi: 10.1111/apt.16565.
    PubMed     Abstract available
    
    
    
41. BASNAYAKE C, Geeraerts A, Pauwels A, Koek G, et al
    Systematic review: duodenogastroesophageal (biliary) reflux prevalence, symptoms, oesophageal lesions and treatment.
    Aliment Pharmacol Ther. 2021;54:755-778.
    PubMed     Abstract available
    
    
    August 2021
42. ZAMANI M, Alizadeh-Tabari S, Hasanpour AH, Eusebi LH, et al
    Systematic review with meta-analysis: association of Helicobacter pylori infection with gastro-oesophageal reflux and its complications.
    Aliment Pharmacol Ther. 2021 Aug 26. doi: 10.1111/apt.16585.
    PubMed     Abstract available
    
    
    
43. ARAI J, Aoki T, Hayakawa Y, Niikura R, et al
    Letter: predictive model for gastric cancer after eradication of Helicobacter pylori-a survival analysis using a deep learning algorithm.
    Aliment Pharmacol Ther. 2021;54:528-529.
    PubMed    
    
    
    
44. LIU Y, Chen M
    Letter: association between the risk of microscopic colitis and use of proton pump inhibitors.
    Aliment Pharmacol Ther. 2021;54:526-527.
    PubMed    
    
    
    
45. CHEN L, Glance S, Garg M
    Letter: response of eosinophilic oesophagitis to proton pump inhibitor therapy-the importance of biopsies at index endoscopy.
    Aliment Pharmacol Ther. 2021;54:521-522.
    PubMed    
    
    
    
46. LUI TKL, Leung WK
    Letter: predictive model for gastric cancer after eradication of Helicobacter pylori-a survival analysis using a deep learning algorithm. Authors' reply.
    Aliment Pharmacol Ther. 2021;54:530-531.
    PubMed    
    
    
    
47. KATZ P
    Editorial: non-erosive reflux disease is often not GERD-time to change the definition or abandon the term?
    Aliment Pharmacol Ther. 2021;54:493-494.
    PubMed    
    
    
    July 2021
48. KIM YD, Wang J, Shibli F, Poels KE, et al
    No association between chronic use of ranitidine, compared with omeprazole or famotidine, and gastrointestinal malignancies.
    Aliment Pharmacol Ther. 2021 Jul 12. doi: 10.1111/apt.16464.
    PubMed     Abstract available
    
    
    
49. ROGERS BD, Gyawali CP
    Editorial: post-reflux swallow-induced peristaltic wave in eosinophilic oesophagitis-more questions than answers?
    Aliment Pharmacol Ther. 2021;54:188-189.
    PubMed    
    
    
    
50. FRAZZONI M, Frazzoni L, de Bortoli N, Savarino E, et al
    Editorial: post-reflux swallow-induced peristaltic wave in eosinophilic oesophagitis-more questions than answers? Authors' reply.
    Aliment Pharmacol Ther. 2021;54:190-191.
    PubMed    
    
    
    
51. OUDE NIJHUIS RAB, Sweis R, Abdul-Razakq H, Schuitenmaker JM, et al
    Characterisation of patients with supine nighttime reflux: observations made with prolonged wireless oesophageal pH monitoring.
    Aliment Pharmacol Ther. 2021;54:144-152.
    PubMed     Abstract available
    
    
    June 2021
52. RIBOLSI M, Frazzoni M, Marabotto E, De Carlo G, et al
    Novel impedance-pH parameters are associated with proton pump inhibitor response in patients with inconclusive diagnosis of gastro-oesophageal reflux disease according to Lyon Consensus.
    Aliment Pharmacol Ther. 2021 Jun 28. doi: 10.1111/apt.16481.
    PubMed     Abstract available
    
    
    
53. SALVO EM, Ferko NC, Cash SB, Gonzalez A, et al
    Umbrella review of 42 systematic reviews with meta-analyses: the safety of proton pump inhibitors.
    Aliment Pharmacol Ther. 2021 Jun 11. doi: 10.1111/apt.16407.
    PubMed     Abstract available
    
    
    
54. YADAV Y, Talley NJ
    Editorial: microscopic colitis linked to NSAIDs but not proton pump inhibitors.
    Aliment Pharmacol Ther. 2021;53:1324-1325.
    PubMed    
    
    
    April 2021
55. FRAZZONI M, Frazzoni L, De Bortoli N, Russo S, et al
    Response of eosinophilic oesophagitis to proton pump inhibitors is associated with impedance-pH parameters implying anti-reflux mechanism of action.
    Aliment Pharmacol Ther. 2021 Apr 15. doi: 10.1111/apt.16371.
    PubMed     Abstract available
    
    
    March 2021
56. EUSEBI LH, Telese A, Cirota GG, Haidry R, et al
    Systmatic review with meta-analysis: Risk factors for Barrett's oesophagus in individuals with gastro-oesophageal reflux symptoms.
    Aliment Pharmacol Ther. 2021 Mar 11. doi: 10.1111/apt.16321.
    PubMed     Abstract available
    
    
    
57. HUSSAIN N, Shung DL
    Editorial: vitamin K antagonists versus direct oral anticoagulants in upper gastrointestinal bleeding.
    Aliment Pharmacol Ther. 2021;53:751-752.
    PubMed    
    
    
    
58. LABENZ C, Schattenberg JM
    Letter: proton pump inhibitor use and bone fracture risk-a mechanistic point of view. Authors' reply.
    Aliment Pharmacol Ther. 2021;53:673.
    PubMed    
    
    
    
59. SUGIYAMA T
    Letter: proton pump inhibitor use and bone fracture risk-a mechanistic point of view.
    Aliment Pharmacol Ther. 2021;53:671-672.
    PubMed    
    
    
    
60. ROCCO A, Compare D, Sgamato C, Coccoli P, et al
    Editorial: proton pump inhibitor use in cirrhosis-a piece of the puzzle. Authors' reply.
    Aliment Pharmacol Ther. 2021;53:665-666.
    PubMed    
    
    
    
61. CELSA C, Camma C
    Editorial: proton pump inhibitor use in cirrhosis-a piece of the puzzle.
    Aliment Pharmacol Ther. 2021;53:663-664.
    PubMed    
    
    
    February 2021
62. ABDEL-AZIZ Y, Metz DC, Howden CW
    Review article: potassium-competitive acid blockers for the treatment of acid-related disorders.
    Aliment Pharmacol Ther. 2021 Feb 16. doi: 10.1111/apt.16295.
    PubMed     Abstract available
    
    
    January 2021
63. LEUNG WK, Cheung KS, Li B, Law SYK, et al
    Applications of machine learning models in the prediction of gastric cancer risk in patients after Helicobacter pylori eradication.
    Aliment Pharmacol Ther. 2021 Jan 24. doi: 10.1111/apt.16272.
    PubMed     Abstract available
    
    
    
64. GOURIOU C, Bouguen G, Lahmek P, Pelaquier A, et al
    Outcomes of upper gastrointestinal bleeding are similar between direct oral anticoagulants and vitamin K antagonists.
    Aliment Pharmacol Ther. 2021 Jan 5. doi: 10.1111/apt.16236.
    PubMed     Abstract available
    
    
    December 2020
65. ROCCO A, Compare D, Sgamato C, Coccoli P, et al
    Impact of proton pump inhibitors on cytochrome P450 activity assessed by (13) C-aminopyrine breath test in patients with cirrhosis.
    Aliment Pharmacol Ther. 2020 Dec 28. doi: 10.1111/apt.16239.
    PubMed     Abstract available
    
    
    November 2020
66. CHAUDHARY S, Mackay D, Pell JP, Morris J, et al
    Upper gastrointestinal bleeding in Scotland 2000-2015: trends in demographics, aetiology and outcomes.
    Aliment Pharmacol Ther. 2020 Nov 18. doi: 10.1111/apt.16170.
    PubMed     Abstract available
    
    
    September 2020
67. LEE PL, Suk FM, Kang YN
    Letter: does tranexamic acid reduce the need for surgery in patients with upper gastrointestinal bleeding?
    Aliment Pharmacol Ther. 2020;52:1088-1089.
    PubMed    
    
    
    
68. MARCUS EA, Pisegna JR
    Editorial: tegoprazan-the newest advance in the management of acid-related diseases.
    Aliment Pharmacol Ther. 2020;52:1074-1075.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Peptic Ulcer is free of charge.